Aims: Most sono/photosensitizers of cancer sonodynamic/photodynamic therapy (SOT/PDT), such as hypocrellin SL052, are water-insoluble, therefore restricting their clinical applications. In this article, we present a water-soluble nanocarrier to load the SOT/PDT sensitizer SL052 with improved pharmacokinetics and therapeutic efficacy. Materials & methods: Nanoclusters of polyvinylpyrrolidones with SL052 formed water-soluble nanoparticles (SL052-NPs) while retaining the chemical structure of SL052. Results: The experimental results show that SL052-NPs improve the drug's physicochemical properties and significantly enhance the efficacy of SL052 in terms of pharmacokinetics and cancer killing. Water-soluble SL052-NPs can be used to deliver the drug to deep cancer tissues. A potential benefit of SL052-NPs is that polyvinylpyrrolidones can help SL052 evade the reticuloendothelial system, thereby increasing circulation half-life and improving drug biodistribution. Conclusion: SL052-NPs greatly improved the physicochemical properties of SL052 without modifying its chemical structure, allowing for deep-site cancer drug delivery, imaging for diagnosIs, and ultrasound or photocontrolled localized cancer therapy.
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Hypocrellins as sono/photosensitizers for Various polymer architectures provide a direct SOT/PDT have recently received much research means to control the overall size of NP aggre attention [10] [11] [12] [13] [14] owing to high quantum yields gates, interparticle spacing between particles and of singlet oxygen and excellent light-induction collective behavior in NP ensembles [4) .
attributes. However, the longest wavelength In additional to conventional radiotherapy absorbance band of hypocrellins, including and chemotherapy, sonodynamiclphotodynamic hypocrellin A and hypocrellin B, is 584 nm , therapy (SOT/PDT) is a newly developed therapy which is lower than the absorption of the photo for cancer treatment. Ultrasound is used in SOT therapeutic window (600-900 nm) (FIGURE 1) . To to enhance the cytotoxic effects of drugs known solve this problem, hyprocellin B is aminated to as sonosensitizers, which are extremely sensitive form a proprietary SL052, as shown in FIG URE 1,  to ultrasound. With the irradiation of ultrasound, which was synthesized at Quest PharmaTech sonosentizers and ultrasound can achieve syner Inc. (Edmonton, Canada and carbonyl groups [16J. However, its insolubil The ultrasound instrument (ULTRA SX) used ity (the drug floats on top of the aqueous solu in the study is manufactured by EXCEL TECH tion [FIGURE 2Al) has made SL052 very difficult LTD (Oakville, ON, Canada). The instrument to deliver into the body through conventional can output ultrasound at 1 MHz with adjustable routes, including orally or by an intravenous or power intensities. The 3-[4,5-dimethylthiazol intramuscular injection. Attempts have been 2-yI1-2,5-diphenyl tetrazoliumbromide (MTT) made to make hyprocellins and their deriva Cell Titer 96 Nonradioactive Cell Proliferation tives water soluble by chemically modifying Assay Kit was purchased from Promega their molecular structures, including the for (Madison, WI, USA). All the above chemicals mation of a complex with metal ions, or the were used without any further purification. formation of Iiposomeslmicelles [I7J. However, these approaches were not very successful, as • Synthesis of SL052-NPs evidenced by low cellular uptake and poor bio The precipitation method was used to prepare logical compatibility. In this article, we report SL052-NPs. The detailed synthesis protocol is as the use of polyvinylpyrrolidone (PVP) as the follows: 1.5 ml of0.5% (7.5 mg/ml) PVP aqueous nanocarrier to load SL052, forming biocom solution was added to 6 ml of water and stirred patible NPs (SL052-NPs in FIGURE 2B & 2C) that to form a mixture at room temperature. After are water soluble while maintaining their func 10 min, 1.59 ml of4.6 mM SL052 in DMSO was tional chemical structure, resulting in better added to the mixture. The resulting solution was biodistribution and cancer killing efficacy. stirred for 10 min in a dark environment to obtain nanodispersion. The SL052-NPs were soluble in
Materials & methods
water and showed deep blue color (FIGURE 2C) .
• Materials & equipment Polyvinylpyrrolidone (average molecular Fluorescent SL052-NPs weight: 40,000) was purchased from Sigma Visible NPs will help researchers to trace the inter Aldrich Canada Ltd (Oakville, ON, Canada). action of NPs in the cells. In this study, SL052 Dimethylsulfoxide (DMSO, reagent grade) was and fluorescein isothiocyanate formed fluorescent purchased from Fisher Scientific Co. (Ottawa, SL052-NPs. A total of 1.5 ml of 0.5% PVP aque ON, Canada). The hydroxybenzaldehyde ous solution was added to 6 ml of water, then derivative, SL052, was provided by Quest stirred to form a mixture at room temperature. PharmaTech Inc. (Edmonton, AS, Canada). After 10 min. A total of 1.59 ml of4.6 mM SL052 Sana/photosensitizer nanoparticles for enhanced cancer therapy RESEARCH ARTICLE 4 HeLa cells) was added into each well of a 96-well plate. After an incubation period of 24 h at 3JOC, either SL052 or SL052-NPs were added to the test cells over 2 h, for a final con centration of 50 Ilg/ml. The cells were treated using ultrasoundllight of the appropriate power and intensity. Old medium was then removed by washing the cells with phosphate buffered saline three times, followed by the addition of 180 III new medium into each well. The cell survivals were then determined by using a tetrazolium compound-based colorimetric method (MTT assay), as described below.
Cell-viability assay
Cell viability was measured using the MTT assay. A total of 20 III of a 5.0 mg/ml solution of MTT reagent dissolved in phosphate buff ered saline (Invitrogen) was added to each well. After 3 h of incubation with MTT reagent, the medium was removed and 200 III of dimethyl sulfoxide was added to dissolve the formazan crystals. The SDT/PDT efficacy was measured by reading the 96-well plate reader at an absor bance of 490 nm. The half maximal inhibitory concentration (IC ) value at a given time point so (expressed as mmol/l) was calculated based on the drug concentratitm producing a 50% reduction in the absorbance value relative to the solvent control absorbance value (100%) . The mean and standard deviation of IC were so calculated based on the data obtained from three separate experiments. Additionally, six replicas were performed for each concentration dose.
• In vivo SOT Male Balb-c mice were given a priming dose of pristane 400 Ill. After 13 days, they were given an intraperitoneal injection of 5 x 10 6 SP/2 cells. Five control mice were left untreated after tumor implant. At 5 days post-tumor implant, the SDT treatment group was given an intra peritoneal injection of 50 mg/kg SL052 NPs in Hank's balanced salt solution (total volume: 0.75 ml). The mice were allowed a 4 h drug .uptake time in subdued lighting. They were then anesthetized with sodium pentobarbi tal and subjected to ultrasound treatment at 1 MHz using a 50 mW power level for five cycles of 2 min ultrasound followed by 1 min without, to give a total delivered dose of 1.5 Kj. The animals were then allowed to recover and kept in subdued lighting for a further 24 h to allow for drug metabolism/excretion.
• In vivo PDT
Male Balb-C mice from Charles River Animal Facility were obtained and allowed to acclima tize for 2 weeks prior to testing. All mice had a bilateral flank implant of 10 x 10 6 EMT-6 murine mammary tumor on each side. The tumors were allowed to grow to at least 5 mm in diameter before drug and light treatment. All treated mice received an intravenous tail-vein injection of6-mg/kg NP solution. The injection comprised 40 III of the supplied NP solution and 60 III ofsterile saline for a total injection volume of 100 Ill. Animals injected with the NP formu lation were divided into two groups. The first group was treated with light 4 h after injection, while the second group was treated with light 24 h after injection. The light treatment for both groups was 100 J/cm 2 at a wavelength of 650 nm with a fluency rate of200 mW from a high-power diode laser via a 400-nm fiber. The tumor was measured and the longest axis was used to cal culate the light spot size. The animals were anes thetized then draped during the light treatment except for the tumor area to prevent exposure in case of uptake by normal tissues. Once treat ment was completed, the animals were allowed to recover and then returned to their cages: The tumor response was monitored daily by caliper measurements of the tumor length, width and thickness. The following formula was used to calculate the tumor volume:
Tumor volume = length. width. thickness. 7r16
• Statistical analysis
Experimental values were determined in six replicas. All values regarding measurement were expressed as means and standard deviations. The one-way analysis ofvariance and Tukey multiple comparison post-tests were used. Differences less than 0.05 (p < 0.05) after correction were considered statistically significant.
Results

• Synthesis of SLOS2
SL052-NPs were synthesized by encapsulat ing SL052 in PVPs. The SL052-NPs exhibited excellent stability without agglomeration in water (for more than 1 year) and various other biological media. The model for forming water soluble SL052-NPs is as follows: after adding the water-insoluble SL052 (FIGURE 2A) into the PVP (FIGURE2B), each SL052 is bound to two or more linear PVP chains with hydrogen bonds between the OH-or NH-groups, and the oxygen of lac tam groups of PVP, which leads to the cro~ link among the linear PVP chains. As a result, water-soluble SL052 NPs are formed (FIGURE 2C) . If the SL052 solution in DMSO is added to water without PVP, we observed that the SL052 was insoluble in water. Therefore, PVP plays an important role in allowing hydrophilic SL052 to become water soluble.
The average size of SL052-NPs is approxi mately 60 nm, as shown in FIGURE 3A. An ana lytical assay was developed to determine SL052 A B 2.5 concentration using a Lambda 900 UV/VISI NIR spectrophotometer. The UV absorption val ues determined by the spectrophotometer with a wavelength absorbance at 657 nm were found to be linearly correlated with SL052 concentrations between 0.042 and 85.9 Ilg/ml. The correlation coefficient was 0.995 (FIGURE 3B). Based on theo retical calculations, there is an average of7 x lOG SL052 molecules in each SL052-NP (refer to the discussion in the SUPPLEMENTARY MATERIALS). FIGURE 3C shows the UV-visible absorption spectra of SL052-NPs in an aqueous solution (FIGURE 3C) . For comparison, the spectrum ofpure SL052 in DMSO is also shown in FIGURE 3C . The spectral patterns of SL052-NPs are similar to those of SL052 in DMSO (FIGURE 3C ). Both of them exhibit significant light absorption around 650 nm, which is located in the red spectral region. The results indicate that the chemical structure of SL052 molecules did not change when they self-assembled into NPs.
To trace the distribution ofSL052-NPs within cells, we labeled SL052-NPs with green fluores cein isothiocyanate. In this study, visible fluo rescent SL052-NPs were used to investigate the cellular uptake and biodistribution ofNPs in the cells (FIGURE 4) . NP: Nanoparticle.
• future science group www.futuremedicine.com As the concentration of SL052-NPs increased, more nanoparticles entered into cells.
time was extended to 2 or more min and the ultrasound intensity was greater than 0.6 wiem' , the ultrasound had obvious cell-killing effects (p < 0.05). Hence, an ultrasound dose of I min of stimulation with an intensity of 0.6 w/cm' was selected for rest experiments in vitro. The optimal time schedule for ultrasound administration was investigated by exposing cells to SL052-NPs for different time periods, and then administrating the ultrasound treat ment. The results in FI GU RE SA demonstrate that incubating cells with SL052-N Ps for 2 hand then applying ultrasound treatment increased cell killing by approximately 20% when com pared with immediately applying ultrasound without incubation (p < 0.05 ). The reason is that more SL052-NPs enter the cells after incubation and enhance the killing effects of ultrasound.
Cellular uptakes
The concentrations of NP-encapsulated SL052 that were taken up by HeLa cells in cell lysate were quantified using the UV-absorption method. After the cells were exposed to various concentrations ofSL052-NPs for 2 h, the average SL052 drug value uptaken by each HeLa cell was determined, as shown in FIG~R.E60. After exposure to SL052-NPs at a concentration of 115 flg /ml for 2 h, each cell uptook 75.23 ± 4 .38 pg SL052, which represents a marked increase when com pared with the 2.46 ± 0.32 pg uptaken by each cell when incubated with the same concentra tion of SL052 in water (not shown in FI GU RE 60) . Enhanced cell uptake of SL052-NPs was also directly confirmed by the confocol microscope images shown in FIGU RE 4.
Ultrasound-activated cytotoxicity of SL052-NPs
To investigate the efficacy of the formulations, the cytotoxicities induced by either SL052 or SL052-NPs were determined by MTT assay. The results for SL052 and SL052-NPs are shown in FIG URES SC and FIGURE 50 , respectively, where the values of IC,o were 60 flg /ml for SL052 and 24 flg/ml for SL052-NPs. The results indicate that SL052-NPs were better than SL052 alone in terms of ultrasound activated cell killing, or SL052-NPs are more sensitive to ultrasound stimulation than SL052 alone by a factor of2.5 .
Stability of SL052-NPs
To determine the stability of the SL052-NPs, we performed cytotoxicity tests for the same drug stored under different temperatures for different durations. Fresh SL052-N P solution was prepared with water to maintain a constant concentration of 50 flg /ml. The samples were then stored at 24, 4 or -20°e. Drug efficacy was determined through observed cytotoxicity using the MTT assay after different storage durations (l day, I week, I month or 2 months). The test results in FI GURE 58 show that the SL052-NPs in solution were stable and effective for at least 2 months when stored at -20°C.
Phototherapy with SL052-NPs in vitro
Because SL052 is a photosensitizer (refer to FIG!;R.E 1; one absorption peak is around 462 nm and another peak is around 617 nm) in addition to being a sonosensitizer, we also evaluated the cyto toxicity ofSL052-NPs when light was applied. A halogen light apparatus was set up, and the power and energy of the light was recorded. A 462 nm filter was then inserted in front of the light source, and the power and energy were recorded again. The halogen lamp was then turned on for 30 min before measurement to obtain a stable meter read ing. After treatment with either SL052 or SL052 NPs for 2 h, HeLa cells were exposed under the C Sono/photosensitizer nanoparticles for enhanced cancer therapy filtered light for 30 s. Power (in watts) and energy (in joules) were recorded after each treatment.
The le value for cells treated with 462 nm light so was 0.52 pg/ml (FIGURE6A) compared with 0.55 pgl ml for those treated with 617 nm (FIGUR£68).
In vivo study of photo/sono activated therapy with SL052-NPs PDT with SL052 NPs After injection of SL052-NPs at doses of 2 or 6 mg/kg. respectively. the tumor-bearing mice were exposed to the light treatment. Once treat ment was completed. the animals were allowed to recover and then returned to their cages. The tumor response was monitored daily by cali per measurements of the tumor length. width and thickness. The in vivo results are plotted in F,GURE7A . All except one mouse subjected to PDT 4 h post-treatment with SL052-NPs at doses of 2 and 6 mg/kg became tumor free after 2 weeks of PDT. The one exception was a mouse from the group treated with SL052-NPs at a dose of 6 mg/kg and then treated with light ; it fell ve ry ill on the first day after treatment and was found dead on the second day. All mice treated with light 24 h postinjection of SL052-NPs remained healthy, but none of the animals had tumor ablation and all had to be euthanized owing to increasing tumor burden. The experi ments were also carried out on the mice that were treated with a dose of 4 mg/kg (F, GURE 7 8) . The mice bearing an original tumor were treated with SL052-NPs for 4 h and then with the PDT. After 2 weeks, the treated mice became tumor free. However, in the group of mice that bore both the original and migrated tumors, after 4 h post treatment with SL052-NPs, the PDT was only administrated to the original tumor but not to the migrated tumor, which resulted in a delayed but steady tumor growth (F, GURE 7 8) .
SDT experiments with SL052 NPs The animals treated with SL052-NPs were exposed to ultrasound, and then monitored daily for general health and body weight. The experimental end point was when the animals became visibly distressed or death resulted through the overnight period. The results are shown in the F,GURE 7C. For tumor-bearing mice, the survival period was approximately 17 days for SDT-treated mice compared with 9 days for the untreated control. 
Discussion
Sonodynamic therapy was chosen because, with out surgery, a form of mechanical energy gener ated by an external ultrasound transmitter can reach deep organs, such as the cervix, prostate and pancreas. As a result, preloaded sonosensitiz ers on malignancy sites buried deep in tissues can enhance the effect ofSOT because these son osen sitizers can be focally activated by ultrasound to achieve cell killing, even at low dosages. However, the poor water solubility ofsome SOT therapeu tic drugs, particularly natural products, such as SL052, seriously limits their clinical applications. Nanotechnology is one methodology that can be used to solve such problems. The nanocluster ofbiocompatible NPs is a new strategy in nanomedicine to provide improved biodistribution and therapeutic efficacy. There are several advantages to this nanoscale strategy in present studies. First, in this study, nanofor mulation played an important role in improv ing the delivery of these drugs by making the drug water soluble without changing its chemi cal structure. Furthermore, nano-modification allowed the drug to be delivered to some malig nancy sites buried deep in tissues that are diffi cult to reach by drugs with poor water solubility. Two major difficulties faced by chemists seek ing to improve the water solubility of drugs with chemical methods are reduced drug efficacy and increased toxicity [18] [19] [20] [21] . Our nano-formulation solved the solubility problem while avoiding both these difficulties. Second, the nanocluster approach provides an easy synthesis protocol with few steps. The nanocarrier was formed in a waste-free manner with 100% encapsula tion of SL052. Finally, nanostructures provide a multifunctional platform. In this study, the therapeutic NPs were conjugated with a visible fluorescent functional group that has been used for the evaluation of drug interaction with tar get cells (FIGUR.E4) . Potentially, SL052-NPs could be bound with specific biomolecules to achieve target delivery.
Additionally, PVP is a nonionic water-soluble polymer that is safe to use and exhibits a wide variety of applications in medicine,. pharmacy, cosmetics and industrial production. In our design, PVPs were used as nanocarriers to form a hollow biodegradable microcapsule loaded with SL052 (SL052-NPs) to overcome the problem of hydrophobicity ofSL052 and prolong the cir culation lifetime of SL052 by prolonging blood circulation, and enhancing permeability and retention [22J. We have shown that SL052-NPs provide markedly improved treatment efficacy over the sonosensitizer SL052 alone, as evidenced by its increased efficacy when ultrasound is applied. SL052 is a natural compound extracted from Hypocrella bambusae, a fungus that grows on bamboo in China and Japan. Both SL052 and SL052-NPs had minimal toxicity without ultra sound or light stimulation (shown in FIGURE 5C ). However, when the drugs were exposed to ultra sound, free radicals were produced that showed cell killing effects. This effect became more pro nounced when the drugs were exposed to 462-or 617-nm light as shown in FIGURE 5C. Compared with conventional radiation and chemotherapy, the ultrasound treatment is much safer and allows doctors to selectively destroy cancers, while limiting the collateral damage often caused by current conventional treatments. Ftirthermore, unlike expensive radiation equipment needed for radiation therapy, the ultrasound device to acti vate SL052-NPs is portable and easily accessible to the general public. This fact is very useful for patients in developing countries or in rural areas where expensive radiation therapy equipment is not available.
The critical reason for the higher efficacy of SL052-NPs over SL052 is that cells uptake more SL052-NPs, as shown in FIGURE 5D , owing to the water solubility ofSL052-NPs. This find ing was also directly confirmed by the confocol microscope images shown in FIGURE 4. This result is directly responsible for tumor suppression at low doses ofSL052-NPs shown in FIGURE 5C & 5D. Furthermore, to achieve the same cell-killing effects, a reduced dosage of SL052-NPs is required compared with SL052 alone, which can also reduce the collateral damage to normal tissues surrounding tumors.
In this study, a new nanoformulation was developed using SL052 that is superior to the source material, and which cannot be achieved by traditional drug formulations. First, nano formulation easily conferred water solubility to SL052 without changing the drug's chemi cal structure. In our study, this formulation showed greater drug efficacy owing to increased drug biodistribution attributed to higher water solubility. Second, SL052-NPs helped deliver the SL052 to cancer tissues embedded deep within the body that would be impossible to reach using insoluble unmodified SL052 products. Third, SL052-NPs combined multiple functions, including imaging along with cancer killing. In addition to sensing and treating functions, PVP also helped SL052 evade the reticuloendothelial system, thereby prolonging circulation half-life and improving drug biodistribution. We are (III future science group www.futuremedicine.com planning to bind the NPs to specific molecules to achieve targeted drug delivery. Fourth, sens ing functions were showcased, which could be used for diagnosis. Fluorescent or other labeling produces NPs with sensing ability for diagnosis. This ability will be significantly enhanced when the NPs are capable of targeted delivery. Finally, ultrasound-controlled drug release for cancer therapy was achieved.
Conclusion
Although SOT is under investigation by researchers across the globe, the science itself is relatively young. To our knowledge, this is the first successful report of nanostructures being used to deliver SL052 to achieve effec tive in vitro and in vivo tumor treatment. These results open up further exploration of biomedical applications of novel SL052-NPs for potential clinical applications in the future.
It is important to note that the chemical func tionalization of SL052 largely determines the efficacy of SL052 drug delivery. The treatment efficacy of SL052-based drug delivery vehicles can be further improved because the current functionalization scheme has not yet fully opti mized. One important advantage of the NP is its potential to combine multiple functional groups, such as targeting ligands, other drugs and multiple molecules, in a single platform to achieve synergistic effects. Targeting ligands on SL052-NPs for tumor-targeted drug delivery is also expected to further enhance treatment efficacy. Using our SL052-NPs in conjunction with diagnosis information and ultrasound, a customizable therapeutic program could be produced, including contI'ol over such aspects as timing, treatment location and dosage. Overall, the reported nanoformulation may help SL052 to achieve a personalizable, image-guided cancer therapy.
Future perspective
Future work for this project will be performed on studies in pharmacology, toxicology and clinical trials.
